Jason Bock, Ph.D.
Dr. Bock is the CEO of CTMC, a joint venture between Resilience and MD Anderson Cancer Center. Formed in May 2022 to bring together innovative academic science with industrial drug development and advanced manufacturing capabilities to rapidly enable cell therapies that impact patients. In 2019, Dr. Bock was recruited by MD Anderson from Teva Pharmaceuticals to build the Biologics Development group. The group purchased a 60,000 SF facility and has since formed multiple partnerships with both MD Anderson faculty and biotech firms to bring their products through the IND process. Previously Dr. Bock was Site Head and VP of Global CMC Biologics in the Specialty R&D Division of Teva Pharmaceuticals. He joined Teva through the acquisition of CoGenesys, a private biotech firm as a spinoff from Human Genome Sciences (HGS) where he worked after completing a PhD at Stanford University in Molecular & Cellular Physiology.
Hossein Borghaei, D.O., M.S.
Dr. Borghaei is Chief of Thoracic Medical Oncology at Fox Chase Cancer Center, where he is also a Professor in the Department of Oncology/Hematology, Co-Director of the Immune Monitoring Facility and the Gloria and Edmund M. Dunn Chair in Thoracic Malignancies. In his clinical practice, Dr. Borghaei has participated in numerous immunotherapy-based clinical trials. He is also the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs. He served as the PI of a phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting. Dr. Borghaei earned his D.O. degree at Philadelphia College of Osteopathic Medicine, did his residency at Graduate Hospital (Philadelphia) and was Chief Fellow, Hematology-Oncology, at Fox Chase Cancer Center.
Guido Cavaletti, M.D.
Dr. Cavaletti is Dean of Research and Professor at the University of Milan-Bicocco, and Senior consultant neurologist and head of the Neuroimmunology Center, S. Gerardo Hospital, Monza (Italy). At the University of Milan-Bicocco, he is Head of the Experimental Neurology Unit at the School of Medicine and Surgery and Director of the Ph.D. program in Neuroscience. He is also Deputy Scientific Director of the Milan Center for Neuroscience (NeuroMI). Dr. Cavaletti is coordinator of the steering committee of the international CI-PeriNoms group on the investigation of chemotherapy-induced peripheral neurotoxicity. He has authored more than 250 peer-reviewed papers. He received his medical degree from the University of Milan and is Board-certified in Neurology.
Robert Wenham, M.D.
Dr. Robert Wenham is both Chair of the Department of Gynecologic Oncology and a Senior Member of the Program of Chemical Biology and Molecular Medicine at Moffitt Cancer Center, as well as Professor in the Department of Interdisciplinary Oncology at the Morsani School of Medicine. Dr. Wenham has a strong interest in research and is a principal investigator for sponsored and investigator-initiated clinical trials to improve cancer care for women, focusing primarily on the use of novel drugs and cellular and other immunotherapies for the treatment of gynecologic cancers. He has received the Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation. He also serves as a chair or member of several clinical trial steering committees, data safety monitoring committees, and advisory boards. Dr. Wenham enjoys the challenge of helping women with complex issues and the opportunity to offer them cutting-edge therapies, from the latest chemotherapy approaches to biological targeted therapies, minimally invasive surgery and clinical trials. He is also an expert in pelvic exenterative surgery, a very complex operation that offers hope of possible cure for certain patients with gynecologic cancer. Dr. Wenham points out that life expectancy for certain women’s cancers, such as ovarian cancer, have dramatically improved over the last 30 years due to advancements in therapy.